Design Therapeutics (DSGN) Common Equity (2020 - 2026)

Design Therapeutics has reported Common Equity for 7 years, with the latest figure at $201.9 million in Q2 2026.

• Common Equity for Q2 2026 came in at $201.9 million, down 5.25% year-over-year; the trailing twelve-month figure through Jun 2026 was $201.9 million (down 5.25% YoY), and the FY2025 annual result was $212.5 million, down 12.22% from the prior year.
• Common Equity slipped to $201.9 million in Q2 2026, from $218.1 million in the prior quarter.
• Over five years, Common Equity peaked at $370.3 million in Q1 2022 and troughed at $199.7 million in Q3 2025.
• A 5-year average of $270.4 million and a median of $265.4 million in 2024 frame the typical range for Common Equity.
• The widest annual swing landed in 2025, when Common Equity declined 20.89%; it then retreated 4.33% in 2026.
• A 5-year view of Common Equity shows it stood at $327.3 million in 2022, then decreased by 15.16% to $277.7 million in 2023, then decreased by 12.82% to $242.1 million in 2024, then retreated by 12.22% to $212.5 million in 2025, then declined by 5.01% to $201.9 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $201.9 million in Q2 2026, $218.1 million in Q1 2026, and $212.5 million in Q4 2025.